Table 2.

Effect of Immobilized 38.13 Anti-CD77 MoAb and B-B6 Anti-CD20 MoAb on BL Cell Viability

% of Cell Viability
RARaRARa + α-CD77RAM-MRAM-M + α-CD20
 
CD77+ cells 
Ramos 91 ± 7 43 ± 9 89 ± 9 90 ± 7 
Daudi 88 ± 9 38 ± 11 87 ± 8 88 ± 7 
Mutu I 87 ± 6 31 ± 7 89 ± 7 91 ± 7 
CD77 cells 
Mutu III 92 ± 9 88 ± 9 90 ± 7 91 ± 8 
VT500 90 ± 8 80 ± 10 87 ± 10 88 ± 8 
Namalwa 89 ± 7 86 ± 8 83 ± 9 87 ± 7 
% of Cell Viability
RARaRARa + α-CD77RAM-MRAM-M + α-CD20
 
CD77+ cells 
Ramos 91 ± 7 43 ± 9 89 ± 9 90 ± 7 
Daudi 88 ± 9 38 ± 11 87 ± 8 88 ± 7 
Mutu I 87 ± 6 31 ± 7 89 ± 7 91 ± 7 
CD77 cells 
Mutu III 92 ± 9 88 ± 9 90 ± 7 91 ± 8 
VT500 90 ± 8 80 ± 10 87 ± 10 88 ± 8 
Namalwa 89 ± 7 86 ± 8 83 ± 9 87 ± 7 

CD77+ BL cells and CD77 BL cells were cultured 24 hours on Petri dishes precoated with: RARa; RARa and 38.13 MoAb (RARa + α-CD77); RAM-M; RAM-M and B-B6 MoAb (RAM-M + α-CD20). The percentage of cell viability was obtained by EB staining and FACS analysis.

Close Modal

or Create an Account

Close Modal
Close Modal